Mercer Global Advisors
HRTX icon

Mercer Global Advisors’s Heron Therapeutics HRTX Stock Holding History

Mercer Global Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32.8K Buy
41,038
+27,658
+207% +$32K ﹤0.01% 3161
2025
Q4 		$17.4K Sell
13,380
-13,329
-50% -$16.5K ﹤0.01% 2826
2025
Q3 		$33.7K Buy
+26,709
New +$42.3K ﹤0.01% 2607
2020
Q1 		– Sell
-41,471
Closed -$975K – 1167
2019
Q4 		$975K Buy
41,471
+2,156
+5% +$47.7K 0.02% 534
2019
Q3 		$727K Buy
39,315
+2,563
+7% +$47.2K 0.02% 576
2019
Q2 		$683K Sell
36,752
-1,800
-5% -$36K 0.02% 573
2019
Q1 		$942K Buy
+38,552
New +$1.01M 0.03% 429

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Mercer Global Advisors's HRTX Position: Q1 2026 in Review

Mercer Global Advisors increased its Heron Therapeutics (HRTX) stake by 207% in Q1 2026, buying an estimated $32K and bringing the position to 41,038 shares worth $32.8K. The position accounts for ﹤0.01% of the portfolio, ranked #3161.

Mercer Global Advisors first reported a position in HRTX in Q1 2019 and has held it in 7 quarters since. The position peaked at $975K in Q4 2019. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Mercer Global Advisors held 41,038 shares of Heron Therapeutics worth $32.8K as of Q1 2026.
  • Mercer Global Advisors bought 27,658 Heron Therapeutics shares in Q1 2026, an estimated $32K.
  • Heron Therapeutics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #3161 holding.
  • Mercer Global Advisors first reported a position in Heron Therapeutics in Q1 2019 and has held it in 7 quarters since.
  • Mercer Global Advisors's Heron Therapeutics position peaked at $975K in Q4 2019.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.